Company
Headquarters: Gamagori, Japan
Employees: 200
CEO: Mr. Ken-Ichiro Hata D.D.S., Ph.D.
¥28.55 Billion
JPY as of July 1, 2024
US$176.8 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company offers autologous cultured epidermis and cartilage to medical institutions for the purpose of medical treatment. It also provides tissue-engineered medical products, which are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured, and then transplanted back to the same patient. In addition, the company researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, it offers regenerative medical products contract development and manufacturing, and contract research services. Japan Tissue Engineering Co., Ltd. was founded in 1999 and is headquartered in Gamagori, As of March 2, 2021, Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Japan Tissue Engineering Co. Ltd has the following listings and related stock indices.
Stock: JPX: 7774 wb_incandescent